Using artificial intelligence to screen for glaucoma in people with diabetes
Tests an artificial intelligence tool for spotting glaucoma in adults with diabetes.
Key facts
- Who runs it
- Singapore Eye Research Institute
- Where
- Singapore, SingaporeSee the site
- Trial code
- Registry title
- Glaucoma Screening Using Artificial Intelligence Assisted Clinical Model in Singapore's Diabetic Eye Screening Program
- Status
- Recruiting
- People taking part
- 1,040 people, planned
- Started
- 17 Nov 2025
- Expected to end
- Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Artificial Intelligence model to detect glaucoma
- Record updated
- 29 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 or type 2 diabetes who attend the named Singapore clinics for diabetic eye screening. It tests an AI tool for finding glaucoma.
- Age
- 21 years and older
- Sex
- All sexes can join.
- Disease stage
- Type 1 or type 2 diabetes. No glaucoma stage is asked for.
Main reasons for not taking part
- Difficulty having retinal photos taken
- Difficulty completing the eye examination steps, as judged by the investigator
- Any other reason against taking part given by the endocrinologist responsible for the patient
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Aged 21 years old and above, with diabetes, including type 1 and type 2,
- Retinal photos of the patients can be taken with the fundus camera in the clinics, regardless of photos' quality, and
- They are willing and capable of providing a written informed consent form
Who cannot take part
- Patients who have difficulty in having retinal photos taken or have difficulties in completing the ocular examination protocols according to investigator's decision
- Any other contraindication(s) as indicated by the endocrinologists responsible for the patients; -
Where in Singapore
- Singapore National Eye CentreSingapore, SingaporeContact: Ching-Yu Cheng, MD, PhDTaking people
About the trial
What the trial wants to find out
Glaucoma is major cause of irreversible blindness and is characterized by optic nerve damage and visual field loss. Screening for glaucoma is challenging due to lack of a simple, accurate, cost-efficient and standardized process. Artificial intelligence, (AI) especially deep learning (DL) algorithms have potential to automate glaucoma detection, but have to be evaluated in real world settings, before public deployment. This study aims to evaluate the screening accuracy of a DL algorithm for glaucoma detection using colour fundus photographs (CFP) in a pragmatic randomised control trial (RCT). The algorithm will be tested in 1040 eligible patients with diabetes, recruited from the Diabetes \& Metabolism Centre's clinics under the Singapore Integrated Diabetic Retinopathy Program (SiDRP) and randomized to 2 arms: AI-assisted model vs current standard of care (grader assessment). The performance of both arms will be compared to performance of study ophthalmologist in diagnosing glaucoma. We hypothesize that the DL model has better screening performance in detecting glaucoma in the community, compared to the current practice method.
The 2 groups in the trial
- Artificial Intelligence Assisted ArmExisting treatment, for comparison
In this arm, human graders will review fundus photographs for glaucomatous features with the aid of output generated by an AI model trained to detect glaucoma. The AI output will be available during grading to support decision-making.
Treatment: Artificial Intelligence model to detect glaucoma
- Current practice armPlacebo, for comparison
Graders will assess fundus photographs for glaucoma following standard clinical practice, using a pre-specified and established set of diagnostic criteria without access to AI-generated outputs.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pragmatic Randomized Controlled Trial of a New Artificial Intelligence-Assisted Clinical Model in Opportunistic Screening for Glaucoma in the Singapore Integrated Diabetic Retinopathy Program
- Plain-language title
- Using artificial intelligence to screen for glaucoma in people with diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 January 2026